Ionis Pharmaceuticals’ Revenue Growth Rate

Revenue growth rate

Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.

Ionis Pharmaceuticals’ Revenue Growth Rate

Quarterly revenue performance

Ionis Pharmaceuticals reported revenues of $117.7 million during the second quarter, representing 5.0% growth in revenues compared to $112.3 million during the second quarter of 2017. Ionis reports revenues from two categories—commercial revenues from the Spinraza royalties and other licensing and royalty revenues, as well as research and development revenues under the collaborative agreements.

This increase in revenues was driven by the growth in commercial revenues from Spinraza royalties during the second quarter. The detailed revenue performance and key products portfolio numbers are discussed in the next article.

Half-yearly performance in 2018

Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018. This growth represented a 15.0% YoY increase from its revenues of $228.0 million during the first half of 2017.

The revenue growth in the first half of 2018 was driven by an increase in the commercial revenues from the Spinraza royalties. The amortization of upfront payments due to the collaboration with Biogen (BIIB) also contributed to this revenue growth during the first half of 2018.

The SPDR S&P Biotech ETF (XBI) holds 1.4% of its total investments in Ionis Pharmaceuticals (IONS), 1.4% in Alexion Pharmaceuticals (ALXN), and 1.3% in Vertex Pharmaceuticals (VRTX).